Research Tracker›Biomarker Atlas›Marker Pages›Amyloid-fibrin microclots

Amyloid-fibrin microclots: biomarker evidence

Amyloid-fibrin microclots appears in 1 entry of the OSMF biomarker atlas, covering Long COVID. Across those entries it is elevated in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Long COVID

Where Amyloid-fibrin microclots is reported

Also listed as: Fibrin(ogen) amyloid deposits

ConditionDirectionCompared againstAssociated symptomsSource
Long COVID↑ elevatedhealthy controlsMicrovascular occlusion, hypoperfusionPretorius et al. 2023

Frequently asked questions

In which conditions is Amyloid-fibrin microclots altered?

In the OSMF atlas Amyloid-fibrin microclots is reported in Long COVID. It is elevated in 1 across 1 entries.

Is there a standard clinical test for Amyloid-fibrin microclots?

The atlas entries for Amyloid-fibrin microclots do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Amyloid-fibrin microclots result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Amyloid-fibrin microclots across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/amyloid-fibrin-microclots.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.